Personal investment isn’t a liability in biotech leadership, but rather, a competitive advantage, writes Lisa Ricciardi, CEO ...

GLP-1 therapies created a consumer-driven market for pharmaceuticals that pairs digital access, partnerships, and retention ...

FDA’s final SIUU guidance loosens some off-label communication rules, but drugmakers still face strict compliance demands to ...

On this week's episode of the Business of Biotech, five-time public company CFO and seven-time public company board member Allan Shaw talks about why FDA decision-making feels less predictable, and ...

On this week's episode of the Business of Biotech, we speak with Dr. Sarfaraz Niazi, Ph.D., about how biosimilar regulations have taken shape, from early FDA uncertainty to citizen petitions, lawsuits ...

As life sciences companies move from the laboratory to the market, the relationship between the commercial leader and the board becomes both more complicated and more consequential. When it works well ...

For much of the past two decades, the geography of pharmaceutical innovation was relatively stable. Discovery and capital clustered in hubs such as Boston, San Diego, and Basel. Asia played an ...

The era of outsourced regulatory work and rented thinking is ending. Agentic AI makes in-house capability inevitable, if leadership has the nerve to build it. Every biopharma CEO now claims to run an ...

Bringing a therapy from early research to patient delivery requires more than innovation—it demands coordination, data integrity, and scalable operations at every step. Explore how an end-to-end ...

On this week's episode of the Business of Biotech, we talk with NervGen leaders Adam Rogers, M.D., and Rich Macary about NVG-291, a daily neuroreparative peptide designed to restore function in ...

A Germany-based biopharmaceutical company marketing products across Europe was facing increasing complexity in managing its global pharmacovigilance (PV) operations. With oversight of more than 2,300 ...

On this week's episode of the Business of Biotech, Brett Monia, Ph.D., CEO at Ionis Pharmaceuticals, talks about how antisense oligonucleotides (ASO) graduated from a late-1980s lab concept to real ...